Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...
This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback